Percheron Therapeutics has announced that it will investigate avicursen (ATL1102) in other indications besides Duchenne muscular dystrophy (DMD) following disappointing Phase IIb results last ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback